Norsk

Påminnelse: Targovax arrangerer investormøte 27. september

Report this content

2022 har vært et veldig aktivt år for Targovax og vår sektor, og vi inviterer til et investormøte tirsdag 27. september, 2022. DNB vil gi en analytikers syn på bioteknologimarkedet, etterfulgt av presentasjoner fra Targovax med fokus på sirkulær RNA. Vi avslutter arrangementet med en mulighet for å snakke med medlemmer av vårt lederteam i en uformell setting med mat og forfriskninger.

Targovax’ lederteam vil presentere på norsk og er tilgjengelig for spørsmål under det sosiale arrangementet.

Dato: Tirsdag 27. september
Tid: 17.00-19.00
Sted: Sentralen, Øvre Slottsgate 3, Oslo

  • En analytikers syn på bioteknologimarkedet
    • o Dr. Geir Hiller Holom, senior aksjeanalytiker i DNB Markets
  • Targovax Business Oversikt
    • o Dr. Erik Digman Wiklund, administrerende direktør i Targovax
  • Sirkulær RNA (circRNA) - det mest nyskapende innen RNA-terapi, oppdaget i Skandinavia
    • o Dr. Thomas Hansen, VP Research i Targovax

Det blir uformell Q&A og servering av mat fra kl 17:45.

Lubor Gaal, finansdirektør og Andreas Storsve, VP Business Development, vil også være til stede.

Påmelding sendes til renate.birkeli@targovax.com

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful studies demonstrating clinical efficacy and providing deep mechanistic insights, the Targovax platform is being expanded into delivery of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, due to enter the clinic in the second half of 2022. This provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.

Abonner